Connection

Peter Verhamme to Factor Xa Inhibitors

Back to Details
This is a "connection" page, showing publications Peter Verhamme has written about Factor Xa Inhibitors.
Peter Verhamme
Connection Strength
0.675
Factor Xa Inhibitors
  1. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
    View in: PubMed
    Score: 0.127
  2. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thromb Res. 2018 08; 168:121-129.
    View in: PubMed
    Score: 0.126
  3. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018 05 22; 71(20):2306-2315.
    View in: PubMed
    Score: 0.124
  4. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
    View in: PubMed
    Score: 0.121
  5. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 03 30; 376(13):1211-1222.
    View in: PubMed
    Score: 0.115
  6. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018 04 10; 2(7):788-796.
    View in: PubMed
    Score: 0.031
  7. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018 02; 16(2):209-219.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.